AveXis Inc (NASDAQ:AVXS) CEO Sean P. Nolan sold 10,000 shares of the firm’s stock in a transaction on Wednesday, March 7th. The shares were sold at an average price of $129.47, for a total value of $1,294,700.00. Following the completion of the sale, the chief executive officer now directly owns 10,000 shares in the company, valued at approximately $1,294,700. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
AveXis Inc (NASDAQ AVXS) traded up $3.03 on Friday, hitting $136.93. 422,973 shares of the stock were exchanged, compared to its average volume of 360,875. The stock has a market cap of $4,917.53, a price-to-earnings ratio of -18.99 and a beta of 2.02. AveXis Inc has a 12-month low of $65.23 and a 12-month high of $137.91.
AveXis (NASDAQ:AVXS) last announced its earnings results on Tuesday, February 27th. The company reported ($2.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.64) by ($0.91). equities research analysts predict that AveXis Inc will post -7.63 earnings per share for the current year.
Several research analysts recently issued reports on the company. BidaskClub raised AveXis from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Chardan Capital restated a “buy” rating and issued a $135.00 target price on shares of AveXis in a research note on Friday, January 5th. UBS Group set a $122.00 target price on AveXis and gave the company a “buy” rating in a research note on Friday, January 5th. Citigroup set a $132.00 target price on AveXis and gave the company a “buy” rating in a research note on Friday, January 5th. Finally, William Blair restated a “buy” rating on shares of AveXis in a research note on Tuesday, January 30th. Three equities research analysts have rated the stock with a sell rating, three have issued a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $123.90.
TRADEMARK VIOLATION WARNING: “Sean P. Nolan Sells 10,000 Shares of AveXis Inc (AVXS) Stock” was first published by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3253573/sean-p-nolan-sells-10000-shares-of-avexis-inc-avxs-stock.html.
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.